

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b> Avecho Biotechnology Limited	
<b>ABN</b>	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Gregory Collier
<b>Date of last notice</b>	10 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Gregory Collier is a Director of Beacon Super Fund Pty Ltd <Beacon Super Fund A/c> and a beneficiary if the fund.
<b>Date of change</b>	10 May 2023
<b>No. of securities held prior to change</b>	<p><b>Direct</b> 5,990,465 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024.</p> <p><b>Indirect</b> <i>Beacon Super Fund Pty Ltd &lt;Beacon Super Fund A/c&gt;</i> 2,000,000 Fully Paid Ordinary Shares</p> <p><i>(Gregory Collier is a Director of the entity and a beneficiary of the fund).</i></p>
<b>Class</b>	<ol style="list-style-type: none"> <li>1. Fully Paid Ordinary Shares</li> <li>2. Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026.</li> </ol>
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>1. 2,000,000</li> <li>2. 3,000,000</li> </ol>

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	1. \$0.006 per Fully Paid Ordinary Share 2. Nil (free attaching options)
<b>No. of securities held after change</b>	<b>Direct</b> 5,990,465 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024.  <b>Indirect</b> <i>Beacon Super Fund Pty Ltd &lt;Beacon Super Fund A/c&gt;</i> 4,000,000 Fully Paid Ordinary Shares.  <i>Beacon Super Fund Pty Ltd &lt;Beacon Super Fund A/c&gt;</i> 3,000,000 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in the Entitlement Offer

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b> Avecho Biotechnology Limited	
<b>ABN</b>	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ross Murdoch
<b>Date of last notice</b>	31 May 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	10 May 2023
<b>No. of securities held prior to change</b>	<b>Direct</b> 1. 1,666,667 Fully Paid Ordinary Shares 2. 3,993,644 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024
<b>Class</b>	1. Fully Paid Ordinary Shares 2. Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026.
<b>Number acquired</b>	1. 1,666,666 2. 2,499,999
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	1. \$0.006 per Fully Paid Ordinary Share 2. Nil (free attaching options)

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<b>Direct</b> 1. 3,333,333 Fully Paid Ordinary Shares 2. 3,993,644 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 3. 2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Entitlement Offer

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

<sup>+</sup> See chapter 19 for defined terms.